Unlock instant, AI-driven research and patent intelligence for your innovation.
Protective effect of notoginseng saponin r1 on small intestinal ischemia-reperfusion injury
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of ischemia-reperfusion and Panax notoginseng saponins, which can be used in medical preparations containing active ingredients, digestive system, organic active ingredients, etc., can solve the problem of no report on the protective effect of small intestine ischemia-reperfusion injury in vivo.
Inactive Publication Date: 2018-08-21
TIANJIN TASLY PHARMA CO LTD
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the protective effect of R1 on small intestinal ischemia-reperfusion injury in vivo has not yet been reported.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0146] tablet
[0147] 【prescription】
[0148] Notoginsenoside R1 100g
[0149] Microcrystalline cellulose 50g
[0150] Micropowder silica gel 3g
[0151] Magnesium stearate 1.5g
[0152] [Preparation method] Take the original and auxiliary materials and pass through a 100-mesh sieve respectively; take notoginseng saponin R1 and microcrystalline cellulose, mix well, use 60% ethanol in an appropriate amount as a binder to make a soft material, pass through a 20-mesh sieve to make granules, and heat at 60°C Dry, take out, pass through a 30-mesh sieve for granulation, add micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1000 pieces, that is to say.
Embodiment 2
[0154] 【prescription】
[0155] Notoginsenoside R1 75g
[0156] Microcrystalline cellulose 37g
[0157] Micropowder silica gel 2.3g
[0158] Magnesium stearate 1.1g
[0159] [Preparation method] Take the original and auxiliary materials and pass through a 100-mesh sieve respectively; take notoginseng saponin R1 and microcrystalline cellulose, mix well, use 60% ethanol in an appropriate amount as a binder to make a soft material, pass through a 20-mesh sieve to make granules, and heat at 60°C Dry it, take it out, pass through a 30-mesh sieve for granulation, add appropriate amount of micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1,000 tablets.
Embodiment 3
[0161] 【prescription】
[0162] Notoginsenoside R1 133g
[0163] Microcrystalline cellulose 66g
[0164] Micropowder silica gel 4g
[0165] Magnesium stearate 2g
[0166] [Preparation method] Take the original and auxiliary materials and pass through a 100-mesh sieve respectively; take notoginseng saponin R1 and microcrystalline cellulose, mix well, use 60% ethanol in an appropriate amount as a binder to make a soft material, pass through a 20-mesh sieve to make granules, and heat at 60°C Dry it, take it out, pass through a 30-mesh sieve for granulation, add appropriate amount of micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1,000 tablets.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses an application of notoginsenoside R1 in preparation of drugs for treating small intestinal mucosal injury, intestinal inflammatory cell infiltration and increase in microvessel permeability caused by ischemia / reperfusion. The application is realized by a way that the notoginsenoside R1 inhibits I[kappa]B[alpha] degradation and metastasis of NF-[kappa]BP65 translocates to cell nuclei, and then inhibits inflammatory cytokine release; the application is realized by a way that the notoginsenoside R1 inhibits leukocytes to swim out of microvessels, so as to avoid infiltration in tissues; the application is realized by a way that the notoginsenoside R1 inhibits cell apoptosis; the application is realized by a way that the notoginsenoside R1 inhibits degradation of vascular intercellular tight-junction proteins and inhibits plasma albumin leakage; and the application is realized by a way that the notoginsenoside R1 regulates ATP5D, increases the content of ATP in intestinal canal tissues, and promotes repair of intestinal mucosa epithelial cells.
Description
technical field [0001] The invention relates to the application of a medicine, in particular to the protective effect of notoginseng saponin R1 on small intestine ischemia-reperfusion injury. Background technique [0002] Small bowel ischemia / reperfusion (I / R) injury can occur in a variety of situations, such as superior mesenteric artery embolization, small bowel bowel transplantation, cardiopulmonary bypass, abdominal aortic aneurysm surgery, trauma, or hemorrhagic shock. Small bowel ischemia-reperfusion can lead to sepsis, systemic inflammatory response syndrome, and multiorgan failure with high morbidity and mortality. [0003] The generation of oxygen free radicals and the initiation of inflammatory cascade reactions have long been considered as the two main mechanisms causing small intestinal ischemia-reperfusion injury. Treatment targeting oxidative stress and inflammatory response has always been the focus of previous research. However, the results are still unsati...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More